The analytical validation of multiple lots of the PRO-Trac TM II ELISA (DiaSorin) for the determination of tacrolimus in whole blood is described. Methods: The analytical parameters assessed included analytical sensitivity, dilution linearity, functional sensitivity, values in samples containing no tacrolimus, intraand interassay precision, supplementation and recovery, metabolite cross-reactivity, interference studies, and method comparisons HPLC-tandem mass spectrometry (HPLC/MS/MS) and the IMx ® Tacrolimus II multiparticle enzyme immunoassay. Where appropriate, assessments were performed according to NCCLS guidelines. Results: The mean analytical detection limit was <0.25 g/L for all lots, whereas the functional sensitivity was 1.0 g/L. Excellent linear correlation (r ‫؍‬ 0.985) was observed for dilution linearity. The intraassay imprecision was <7%, and the total imprecision by ANOVA was <10%. Recovery was 109% ؎ 11%. Metabolite cross-reactivity was consistent with previous reports for this antibody. No interference was observed for 35 tested drugs. Method comparison with HPLC/MS/MS showed no statistically significant differences. Samples exhibited stability through four freeze/thaw cycles and for 1 week at room temperature. Conclusion: These data demonstrate that the PRO-Trac II ELISA is a robust, accurate, and precise tool for the assessment and management of tacrolimus blood concentrations in transplant patients.
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Tacrolimus is a macrolide antibiotic of fungal origin with potent immunosuppressive properties (1 ) . Because of its narrow therapeutic index, large inter-and intrapatient variability in pharmacokinetics, and poor correlation between dose and trough blood concentrations, tacrolimus concentrations in the blood must be monitored regularly (2) (3) (4) . Historically, methods to monitor tacrolimus in the blood have been labor-intensive and lacked sufficient analytical sensitivity.
A manual research ELISA for the determination of tacrolimus in whole blood was developed by Fujisawa Pharmaceutical for use during drug development (5 ) . A manual ELISA based on this research ELISA with readyto-use reagents and a methanol extraction was introduced by DiaSorin (INCSTAR) in 1994. A second-generation ELISA was developed in 1996 that eliminated the organic extraction techniques and shortened the overall procedure to Ͻ4 h (6 ) . The details of this procedure have been reported previously (6 ) . Here we report the analytical validation of multiple production lots of this assay.
Materials and Methods tacrolimus assays
The PRO-Trac TM II FK506 ELISA assay (DiaSorin Inc., Stillwater, MN) was performed according to the procedures detailed in the product insert. This procedure has been reported in detail previously (6 ) . The only modification of the reported procedure utilized in the current study was an increase in the temperature (from 70°C to 75°C) required to halt proteolysis. Unless otherwise noted, all performance studies were performed on representative kits from three independent production kit lots. The IMx ® Tacrolimus II MEIA assay (Abbott Laboratories) was performed according to the procedures detailed in the product insert. This procedure has been reported previously (7 ) . HPLC-tandem mass spectrometry (HPLC/MS/MS) analysis of clinical tacrolimus samples
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was performed by an independent reference laboratory using a previously published method (8 ) with a detection limit of 0.1 g/L.
samples Supplemented samples. Powdered tacrolimus (Ͼ98% purity; Fujisawa Pharmaceutical), was dissolved in methanol at a high concentration to obtain a stock tacrolimus concentrate. Supplemented samples were prepared in EDTA whole blood by the addition of stock tacrolimus concentrate such that the final methanol concentration was always Ͻ10 mL/L.
Clinical samples. Clinical samples were obtained from a multisite clinical trial to be described in detail elsewhere. In this study, 111 liver transplant patients from six clinical sites were followed prospectively for 90 days posttransplantation. The clinical sites involved in this study were the Mount Sinai Medical Center, New York, NY; the University of Miami School of Medicine, Miami, FL; the University of Pittsburgh School of Medicine, Pittsburgh, PA; the University of Pennsylvania Medical Center, Philadelphia, PA; the University of Wisconsin Hospitals and Clinics, Madison, WI; and Emory University Hospital, Atlanta, GA. All patients provided informed consent, and all procedures and protocols were approved by the institutional review boards of the respective clinical sites. Whole blood tacrolimus concentrations in patients were assessed 15 times during this interval with both the PRO-Trac II ELISA and the IMx Tac I microparticle enzyme immunoassay (MEIA). Blood samples were collected three times per week during weeks 1 and 2, twice per week during weeks 3 and 4, once per week during weeks 5 and 6, and one sample every 2 weeks during weeks 7 through 12. These samples were aliquoted and frozen at the clinical site.
Fifty subjects were randomly chosen from four clinical sites for HPLC/MS/MS analysis. Three samples from each subject, for a total of 150 samples, were chosen to represent early, middle, and late time points in the study. Samples were chosen without consideration of the clinical laboratory results. A subset containing 31 samples from 22 patients with serum bilirubin concentrations Ն30.0 mg/L was analyzed separately. Method comparison studies with the IMx Tacrolimus II MEIA were completed on 95 of the original 150 samples that contained sufficient volume for reanalysis.
Nondosed normal samples. Samples from healthy volunteers not receiving tacrolimus were assessed as part of the interference studies. The study was performed on EDTA whole blood from 25 healthy, nonmedicated volunteers, assessed as unknowns with one kit lot of materials. Twelve males and 13 nonpregnant females were included in this study.
analytical methods
Detection limit. The minimum detectable concentration was assessed as the minimum analyte concentration that could be discriminated from zero according to a previously reported procedure (6 ) . The minimum detectable concentration was determined with fresh enzyme conjugate and conjugate near its labeled expiration. Briefly, 10 replicates of the zero and A calibrators were assessed in a single assay. The apparent concentration based on the absorbance at 2 SD below the mean absorbance of the zero calibrator was used to determine the minimum detectable concentration according to a standard equation (6, 9 ) . The minimum detection limit was determined on three independent production lots.
Dilution linearity. Dilution linearity was assessed by serially diluting nine supplemented whole blood samples (initial concentrations 60, 50, 40, 30, 25, and 20 g/L) and 20 clinical samples with the zero calibrator as described in the package insert and assaying the diluted samples as unknowns. All samples were diluted to at least 1:16. The results were plotted as a least-squares linear regression of the expected concentration vs the observed concentration. The undiluted clinical sample values, as determined in the assay, were used to establish the expected values for subsequent dilutions but were not used in the construction of the regression plot. Dilution linearity was determined for clinical and supplemented samples separately and combined and for each lot of material.
Functional sensitivity. Because the minimum detectable concentration was less than the A calibrator and was within a portion of the curve that is mathematically invalid for extrapolation (10 ), a functional sensitivity was determined. The functional sensitivity was defined as the concentration at which the mean interassay CV exceeded 15%. This was determined by diluting two clinical samples with the zero calibrator according to the product insert into the range of 0.5-2.0 g/L. These samples were then assayed in three assays to establish an interassay CV. The data were analyzed by nonlinear regression of the observed concentration vs CV.
Supplementation and recovery. Supplementation and recovery studies were performed by the addition of kit calibra-
, and E (30 g/L) to 15 clinical samples. The values of samples without added calibrator as determined by HPLC/MS/MS analysis (8 ) and the concentrations of the calibrators as determined by HPLC/MS/MS were used to determine the expected values for subsequent dilutions. Recoveries were calculated as the measured concentrations divided by the expected concentrations and expressed as percentages.
Precision. Intra-and interassay imprecision was determined for all three lots of components. Intraassay imprecision was determined by assaying 10 extractions of the kit controls and three EDTA-whole blood controls supplemented with tacrolimus at three concentrations across the calibration range. Interassay imprecision was determined by assaying two extractions of the three supplemented samples in 20 assays over a minimum of 20 days according to guidelines suggested in NCCLS Precision Performance Guideline EP5-T2 (11 ) . Data from this study were analyzed by ANOVA. A second interassay imprecision study was conducted among three of the clinical study sites. Patient samples were aliquoted and distributed to each site for proficiency testing as part of the study protocol. The absolute number of samples varied among sites because the use of sample materials varied among sites. Metabolite cross-reactivity. Tacrolimus metabolites MI through MVII were the generous gift of Fujisawa Pharmaceutical, Osaka, Japan. Metabolite cross-reactivity was assessed by adding 5 g/L of each metabolite (MI-MVII) into a whole blood control containing 3.0 g/L parent drug. Cross-reactivity was assessed according to the equation:
Interference studies. Compounds to be tested for interference were obtained from commercial sources at the highest purities available. Azithromycin and fluconazole were gifts from Pfizer, New York, NY. Ketoconazole and phenytoin were obtained as US Pharmacopiea reference material. Clarithromycin was a gift from Abbott Laboratories, Abbott Park, IL. Itraconazole was a gift from Janssen Pharmaceutica, Titusville, NJ. Prednisone was provided by Seraloids. Ganciclovir was a gift from Roche Pharmaceuticals, Palo Alto, CA. The remaining compounds were obtained from Sigma Chemical. Interference by commonly coadministered drugs was examined by the addition of the test compound to aliquots of EDTA whole blood with tacrolimus added to a concentration of 3.8 g/L. Compounds were tested at concentrations ϳ2.5-fold higher than the expected therapeutic concentrations. Interference studies were conducted on only one lot of kits. Concentrated stock solutions of the test drugs were prepared in appropriate solvent vehicles. Vehicle controls were also prepared for each solvent. Control samples, vehicle control samples, and test samples were assayed in replicates of five each. Compounds were considered to be interfering if the mean assay result of the test sample was outside the expected 2 SD range of the control samples (12 ). When the vehicle controls demonstrated a vehicle effect, the 2 SD range of the vehicle control was used.
Anticoagulant studies. The influence of heparin as an alternative anticoagulant was examined in split patient samples drawn at one clinical site. Blood samples (n ϭ 15) were drawn into both EDTA and heparin Vacutainer Tubes and processed together on the same day by the same technician.
Sample stability studies. To examine the stability of tacrolimus samples, several studies were conducted. Fresh split clinical samples (n ϭ 33) were compared with paired samples stored frozen for at least 48 h. One aliquot was analyzed the same day it was obtained, whereas the second aliquot was frozen for a minimum of 48 h before analysis. Frozen clinical samples (n ϭ 15) were aliquoted and subjected to one to four freeze/thaw cycles and analyzed in a single assay. Finally, clinical samples (n ϭ 20) were maintained at room temperature for a period of 7 days. These samples were analyzed on days 0, 1, 2, 3, 4, and 7.
Results
The analytical performance of the PRO-Trac II ELISA is summarized in Table 1 . The mean (Ϯ SD) minimum detectable concentration observed over the shelf-life of the kit was 0.17 Ϯ 0.06 g/L. The value reported in the product insert (0.23 g/L) represents the upper limit of this 1 SD range. Both values are less than the A calibrator (0.3 g/L) and represent extrapolations ( Table 1) . As expected, nondosed EDTA samples from healthy volunteers gave concentrations less than the reportable lower limit of the assay (0.3 g/L).
Linearity of dilution is an important assay characteristic for the ability to assess out-of-range samples and maintain the accuracy of the final determination. Dilution linearity was demonstrated across the assay range of 1-30 g/L (Table 1 and Fig. 1 ). There was no significant difference between the dilution linearity of clinical samples or whole blood samples with added tacrolimus.
Because the minimum detectable concentration was below the reportable range for the assay, a functional sensitivity was determined. The dilution linearity of the clinical samples utilized to determine the functional sensitivity was confirmed by least-squares linear regression of the mean observed values vs the expected values based on the assay values of undiluted samples. The resulting regression equation was: Observed ϭ 0.97 (expected) ϩ 0.1; r ϭ 0.997 (data not shown). Analysis of these samples by nonlinear regression is shown in Fig. 2 , with the resulting functional sensitivity between 0.8 and 1.0 g/L. Intra-and interassay imprecision was determined as described above. Intraassay imprecision was 1.9 -6.2%, as shown in Table 1 . Total imprecision evaluated at three concentrations across the assay range was Ͻ10% (Table 1) . When analyzed by ANOVA, total imprecision of the 20-day precision studies was Ͻ10% (6.8 -7.9%) as shown in Table 2 . The interassay precision data collected at individual clinical sites with 10 aliquoted patient samples are listed in Table 3 . These data suggest that the expected imprecision in a clinical laboratory setting is 10 -15%. Supplementation and recovery studies were performed to assess the accuracy of the assay. These studies were performed utilizing clinical samples and materials readily accessible to the clinical laboratory. The mean recovery across the range of the assay from 2.5 to 30 g/L was 109% Ϯ 11%.
Least-squares linear regression analysis (Fig. 3) shows a good correlation between the two commercially available methods [IMx Tacrolimus II ϭ 1.04(PRO-Trac II) ϩ 2.2; r ϭ 0.89], although they do not return statistically equivalent values for the same samples. A mean difference of 2.7 g/L was seen between the two methods. This difference was statistically significant by the Student Metabolite cross-reactivity was assessed as described above (Table 6 ). Metabolites MII, MIII, and MV exhibited cross-reactivities of 84%, 36%, and 42%, respectively. This metabolite cross-reactivity is consistent with previously published reports for this antibody (13 ) .
Thirty-five commonly coadministered drugs were assessed for potential interference in the PRO-Trac II assay system. None of the tested compounds exhibited interference with the PRO-Trac II ELISA. These data are summarized in Table 7 .
The effects of various sample storage conditions are summarized in Table 8 . The comparison of fresh samples to frozen samples was conducted with 33 clinical samples. The mean difference between fresh and frozen samples was Ϫ0.5 Ϯ 1.4 g/L. Sample stability was also assessed under repeated freeze/thaw conditions. Fifteen clinical samples were subjected to one to four freeze/thaw cycles. The zero freeze/thaw value was then used to calculate the difference from baseline for each sample after each cycle.
The mean differences from baseline ranged from Ϫ0.6 to 0.7 g/L.
Finally, samples were examined over the course of 1 week of storage at room temperature. The difference from the day 0 value was calculated for each sample on days 1, 2, 3, 4 and 7. The mean differences for all samples ranged from Ϫ0.5 to 0.8 g/L The mean difference for individual samples over all time points ranged from Ϫ0.5 to 1.4 g/L. There was no significant trend in the mean difference with time of storage.
The use of heparin as an alternative anticoagulant was examined in fresh clinical samples. The mean difference between EDTA and heparin samples from clinical subjects was Ϫ0.7 Ϯ 1.5 g/L. These data are summarized in Table 8 .
Discussion
At the present time, there are six generally used methods for the measurement of tacrolimus in whole blood (14 ) . These methods include receptor-binding, bioassay, pentamer formation, HPLC with various detection methods, MEIA, and ELISA technologies. Because of the differences in methodologies, extraction procedures, and metabolite recognition, results are not interchangeable among all methods.
Receptor-binding assays for tacrolimus have been developed using purified immunophilins (FKBPs) (15 ) . Although receptor-binding assays show promise, the results indicate that this method also measures substantial metabolite concentrations (14 ) . Various HPLC methods have been reported, although these methods generally suffer a lack of sensitivity because there is no chromophore or ultraviolet-absorbing structure in the molecule (16 -19 ) . 
Mean differences vs
a Student paired t-test. Table 5 . Percentages of samples exhibiting absolute differences from HPLC/MS/MS values at specified thresholds.
HPLC/MS and HPLC/MS/MS methods that exhibit thenecessary sensitivity have also been developed, but because of equipment requirements, they may not be practical for routine monitoring (8, 20, 21 ) .
Differences in methodologies and values between methodologies makes the choice and validation of an assay method an important necessity for modern clinical laboratories. The data presented here are intended to provide a baseline for validation studies for the PRO-Trac II ELISA for the measurement of tacrolimus in whole blood samples.
The estimated minimum detectable concentration of the PRO-Trac II ELISA was 0.18 g/L, which is 27-fold lower than the 5 g/L suggested as the lower limit of the therapeutic range reported in the Lake Louise Consensus Conference report (4 ) and ϳ10-fold lower than the detection limit of the IMx Tacrolimus II MEIA (22 ) . This analytical value can only be an estimation because the minimum detectable concentration is calculated on the assumption of a linear extrapolation of the calibration curve between the zero and A calibrators. Although this calculation gives a reproducible value, the validity of extrapolations between the zero and A calibrators for four-parameter logistic curve fits is questionable (10 ) . For this reason, we calculated a functional sensitivity of 1.0 g/L based on the concentration at which the mean CV exceeded 15%. This cutoff was somewhat arbitrary because some proficiency testing schemes consider CVs of 20% acceptable (23 ) . The performance of the PRO-Trac II ELISA in the subtherapeutic and low therapeutic ranges is noteworthy (24 ) . The current therapeutic range will likely decrease as transplantation physicians balance organ rejection and toxicity by using lower tacrolimus dosages and additional immunosuppressants (25, 26 ) .
Several estimates of precision were determined. The 20-day interassay estimates performed at DiaSorin are likely to represent the most ideal conditions and can be used to establish a baseline CV for assay performance of ϳ8% across the range of clinically relevant concentrations. The expected assay CV under typical clinical laboratory conditions was shown to be ϳ12% across the range of clinically relevant concentrations.
Supplementation and recovery studies were performed in a format that could be repeated by any clinical laboratory, without accessing pharmaceutical grade tacrolimus. The clinical samples, when diluted with kit calibrators, exhibited recovery of ϳ109%. This is in contrast to the results obtained by other investigators, who have reported decreased recovery using supplemented samples (27 ) . Any differences in sample preparation, such as solvent content, sample size, metabolite contribution, and the loss of parent drug on glass surfaces, make direct comparisons equivocal.
The method comparisons demonstrate a statistical difference between the PRO-Trac II ELISA and the IMx Tacrolimus II MEIA. For better therapeutic drug monitoring, physicians should be aware of the differences. The mean statistical difference of 2.7 g/L suggests a need for monitoring by a single method or notation of the method used when results are reported. Some investigators have reported that the difference between methods may have clinical significance (6, 27 ) . The basis of this difference between methods is currently unclear because both assays utilize the same monoclonal antibody. One could speculate that the differences in soluble vs bound antibody and/or the presence of residual organic solvents utilized for drug extraction may alter antibody affinity and, therefore, contribute to the differences in observed values. Other factors, such as assay incubation times and temperatures, that affect assay kinetics may also play a role in the observed differences.
The agreement between the PRO-Trac II values and HPLC/MS/MS values (mean difference of 0.8 g/L; Table 4) suggests that the concentrations of cross-reactive metabolites in most samples is minimal. The values reported here are consistent with the 96% of total immunoreactivity reported for the parent drug fraction in patients with mild hepatic dysfunction (28 ) , and less than the mean 42% reported for a study of 21 liver transplant patients (29 ). The choice of difference thresholds in the comparison of methods is somewhat arbitrary. The clinical significance of the difference between HPLC/MS/MS and ELISA has not been determined. Both methods exhibit random measurement error, and the "true" value for a given sample when assessed by HPLC/MS/MS is determined only within a range of values. Given the realistic CVs observed in clinical laboratories (Table 3) , the expected differences between methods can be esti- (30 ) . In the subset of the patient population for whom HPLC/ MS/MS sample values were available, samples with bilirubin values Ն30.0 mg/L, an indication of impaired liver function, showed a mean difference of 2.4 g/L. In this case, the difference did not reach statistical significance but may have clinical significance. Although these values are increased relative to HPLC/MS/MS and should probably be flagged to be monitored closely, the general population of impaired liver function subjects in this study did not seem to exhibit the degree of metabolite accumulation observed by other investigators (29, 30 ) .
The anticoagulant studies demonstrated that the PROTrac II ELISA provides the laboratory with potential flexibility and economy in the planning and acquisition of patient samples. The sample stability studies were consistent with previous reports (31 -33 ) .
Overall this analytical validation demonstrates that the PRO-Trac II ELISA is a robust assay for the assessment of tacrolimus whole blood concentrations in liver transplant patients receiving tacrolimus for immunosuppression.
